Novartis reported the SFDA has approved China use of Rasilez® (aliskiren), a treatment for high blood pressure. A first-in-class direct renin inhibitor, Renin is part of the renin-angiotensin-aldosterone system that narrows blood vessels and helps regulate blood pressure. It is approved for use alone or in combination with other hypertensives. More details....

Stock Symbol: (NYSE: NVS)